

## Association of *DIAPH1* gene polymorphisms with ischemic stroke

Zhanyun Ren<sup>1,\*</sup>, Xiaotian Chen<sup>2,3,\*</sup>, Wuzhuang Tang<sup>1</sup>, Jie Li<sup>1</sup>, Song Yang<sup>4</sup>, Yanchun Chen<sup>4</sup>, Xianghai Zhao<sup>4</sup>, Huihua Zong<sup>1</sup>, Chunlan Liu<sup>3</sup>, Chong Shen<sup>3</sup>

<sup>1</sup>Department of Neurology, Affiliated Yixing People's Hospital of Jiangsu University, People's Hospital of Yixing City, Yixing 214200, China

<sup>2</sup>Department of Clinical Epidemiology, Children's Hospital of Fudan University, Shanghai 201102, China

<sup>3</sup>Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing 211166, China

<sup>4</sup>Department of Cardiology, Affiliated Yixing People's Hospital of Jiangsu University, People's Hospital of Yixing City, Yixing 214200, China

\*Equal contribution

Correspondence to: Chong Shen; email: [sc100@126.com](mailto:sc100@126.com)

Keywords: *DIAPH1*, polymorphisms, stroke, mRNA

Received: February 23, 2019

Accepted: December 23, 2019

Published: January 3, 2020

**Copyright:** Ren et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### ABSTRACT

**DIAPH1** is a formin protein involved in actin polymerization with important roles in vascular remodeling and thrombosis. To investigate potential associations of *DIAPH1* single-nucleotide polymorphisms (SNPs) with hypertension and stroke, 2,012 patients with hypertension and 2,210 controls, 2,966 stroke cases [2,212 ischemic stroke (IS), 754 hemorrhagic stroke (HS)] and 2,590 controls were enrolled respectively in the case-control study. A total of 4,098 individual were included in the cohort study. *DIAPH1* mRNA expression was compared between 66 IS [43 small artery occlusion (SAO) and 23 large-artery atherosclerosis (LAA)] and 58 controls. Odds ratio (OR), hazard ratio (HR) and 95% confidence interval (CI) were calculated by logistic and cox regression analysis. Rs7703688 T>C variation was significantly associated with an increased risk of IS [OR (95% CI) was 1.721 (1.486-1.993),  $P=4.139\times 10^{-12}$ ]. Association of rs7703688 with stroke risk was further validated in the cohort study [adjusted HRs (95% CIs) for additive and recessive models were 1.385 (1.001-1.918),  $P=0.049$ , and 2.882 (1.038-8.004),  $P=0.042$ , respectively]. *DIAPH1* mRNA expression was significantly downregulated in IS. In SAO stroke subtype, *DIAPH1* expression has an increased trend among rs251019 genotypes ( $P_{trend}=0.048$ ). These novel findings suggest that *DIAPH1* variation contributes to genetic susceptibility to stroke risk, especially the SAO subtype of IS.

### INTRODUCTION

Stroke ranks as the first leading cause of death in China, with bearing the highest stroke burden in the world [1]. Hypertension is a major risk factor for cerebrovascular disease, including ischemic stroke (IS) and hemorrhagic stroke (HS) [2]. However, characterization of the mechanisms underlying stroke is still incomplete.

Chronic hypertension induces vascular remodeling of cerebral arteries, an essential risk factor for stroke. At

play in this phenomenon is activation of the Rho/Rho-kinase pathway, a crucial modulator of proliferation, motility, and contractility of smooth muscle cells (SMCs) [3–5]. Supporting a key association between Rho/Rho-kinase pathway and cardiovascular diseases via vascular remodeling, our previous studies showed that genetic variations in Rho kinases (*ROCK1* and *ROCK2*) modulate susceptibility to hypertension and stroke [6].

Mammalian homolog of *Drosophila* diaphanous 1 (*DIAPH1*), a formin protein, is a canonical effector for

Rho signaling in humans [7, 8]. After being activated by GTP-bound RhoA, the formin homology-2 domain of DIAPH1 stimulates actin filament assembly at the barbed ends [9]. DIAPH1 mediates vascular remodeling via integration of oxidative stress and signal transduction pathways in SMCs [10]. Besides, DIAPH1 induces pro-platelet formation in megakaryocytes by coordinating the actin and microtubule cytoskeleton [11], which critically impacts blood clotting and thrombogenic processes.

Previous studies have focused on the association of *DIAPH1* polymorphisms and macrothrombocytopenia, hearing loss, blindness, and cancer [12–14]. Importantly, animal experiments have demonstrated that genetic deletion of *DIAPH1* led to infarct size reduction and improved contractile function after myocardial ischemia/reperfusion [15]. However, whether changes in *DIAPH1* expression or function may contribute to stroke incidence has not been established. On account of the important role of *DIAPH1* on vascular remodeling and thrombosis, i.e. two key aspects in the pathophysiology of stroke, we decided to investigate potential associations between *DIAPH1* gene variations and stroke risk.

To this end, we performed case-control and cohort studies to evaluate the association of single-nucleotide polymorphisms (SNPs) in the human *DIAPH1* gene with susceptibility to hypertension and stroke. In addition, the distribution of *DIAPH1* SNP genotypes was typified by measuring *DIAPH1* mRNA expression in peripheral blood mononuclear cells (PBMCs) from IS and hypertensive controls. The present findings provide novel insights about the potential contribution of *DIAPH1* polymorphisms to the pathogenesis of hypertension and stroke.

## RESULTS

### Demographic and clinical characteristics of the study population

Clinic-demographic characteristics of participants in the hypertension case-control study are summarized in Supplementary Table 1. Although study subjects were matched for age (5 year-group), hypertensive cases were on average 3.42 years older than controls ( $P < 0.001$ ). Participants with hypertension had higher BMI, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), glucose (GLU), and a higher rate of type 2 diabetes mellitus (T2DM) than controls ( $P < 0.001$ ). No significant differences in gender, high-density lipoprotein cholesterol (HDL-C), or smoking and drinking statuses were observed ( $P > 0.05$ ).

The characteristics of individuals in the stroke case-control study are summarized in Supplementary Table 2. Significant differences were observed among IS, HS, and controls for age, gender, smoking and drinking habits, hypertension, lipid profiles, and T2DM ( $P < 0.05$ ). Post-hoc multiple comparisons showed that total TC, HDL-C, and LDL-C levels were significantly higher in IS cases than in controls. Compared to controls, HS cases were older, had higher levels of TC and HDL-C, and lower TG levels. These characteristics were adjusted as confounding factors when evaluating the association of *DIAPH1* with stroke.

### Association analysis of *DIAPH1* variants in the case-control study of hypertension

In the case-control study of hypertension, the allele frequencies of the *DIAPH1* rs3805691, rs251019, and rs11954998 SNPs in controls were consistent with Hardy-Weinberg equilibrium (*HWE*), whereas the allele frequencies of rs251018 and rs7703688 were not (*HWE*  $P = 0.004$  and  $P < 0.001$ , respectively). Compared with CC/CT carriers, the rs251019 TT genotype was significantly associated with decreased risk of hypertension, after adjusting for covariates including age, gender, BMI, TC, TG, HDL-C, LDL-C, GLU, smoking status, and drinking status [adjusted odds ratio (OR), 0.791; 95% confidence interval (CI), 0.636–0.984;  $P=0.035$ ] (Table 1).

### Association analysis of *DIAPH1* variants in the case-control study of IS

In the case-control study of stroke, the frequencies of all *DIAPH1* SNPs in controls were consistent with *HWE*. Table 2 shows the results of the association analyses after adjusting for age, gender, smoking status, drinking status, TC, TG, LDL-C, HDL-C, T2DM, and hypertension. The additive model (CC vs CT vs TT) suggested that the rs3805691 variant was associated with decreased risk of IS (adjusted OR=0.782, 95% CI=0.700–0.874,  $P=1.3 \times 10^{-5}$ ). Compared with CC carriers, CT/TT carriers of the rs3805691 SNP were also at lower risk of IS (adjusted OR=0.712, 95% CI=0.622–0.815,  $P=7.986 \times 10^{-7}$ ). Comparable protective effects against stroke were observed for the rs251019 variant in both additive and dominant models. In contrast, rs7703688 and rs11954998 C allele carriers were associated with increased risk of IS [ORs (95% CIs) for the additive model were 1.721 (1.486–1.993) and 1.537 (1.356–1.743),  $P=4.139 \times 10^{-12}$  and  $P=2.058 \times 10^{-11}$ , respectively]. These associations were still significant after Bonferroni correction. No significant association with IS was found for rs251018, nor between the five *DIAPH1* SNPs and HS.

**Table 1. Association analyses of *DIAPH1* SNPs with hypertension in the case-control study.**

SNP	Group	WT/HT/MT	OR(95% CI) <sup>a</sup>			P-values <sup>b</sup>
			Additive model	Dominant model	Recessive model	
rs3805691		CC/CT/TT				
	Case	1136/749/126	1.000(0.902-1.109)	0.994(0.875-1.13)	1.031(0.793-1.341)	0.805
Control	1253/825/132	P=0.996	P=0.931	P=0.820		
rs251018		TT/TG/GG				
	Case	1421/551/40	0.953(0.845-1.075)	1.001(0.878-1.158)	0.572(0.384-0.812)	0.004
Control	1556/574/79	P=0.435	P=0.906	P=0.006		
rs251019		CC/CT/TT				
	Case	980/866/166	0.946(0.859-1.042)	0.985(0.868-1.117)	0.791(0.636-0.984)	0.249
Control	1055/927/228	P=0.261	P=0.813	P=0.035		
rs7703688		TT/TC/CC				
	Case	1672/330/10	0.893(0.766-1.040)	0.942(0.797-1.113)	0.315(0.152-0.650)	<0.001
Control	1818/356/35	P=0.146	P=0.485	P=0.002		
rs11954998		TT/TC/CC				
	Case	1482/488/42	0.943(0.830-1.071)	0.920(0.798-1.060)	1.112(0.710-1.742)	0.205
Control	1590/578/42	P=0.366	P=0.248	P=0.642		

WT wild type, HT heterozygote, MT mutant type;

Rs251018 and rs7703688 were not consistent with *HWE*, with *P* values of 0.004 and 0.001.

a: Adjusted for age, gender, BMI, GLU, HDL-C, LDL-C, TC, TG, smoking status and drinking status.

b: The *P*-values of *HWE* test in controls.

Furthermore, we conducted SNP association analysis stratified by TOAST subtypes (Supplementary Table 8). After covariates adjustment, both rs3805691 and rs251019 were negatively associated with small artery occlusion (SAO) and large-artery atherosclerosis (LAA) under the additive and dominant models. Meanwhile, the rs11954998 and rs7703688 variants were instead associated with increased risks of SAO and LAA under all three genetic models, while no association was detected between rs251018 and either SAO or LAA. Analysis for HS subtypes showed that compared to the TT/TC genotypes, the CC genotype of rs7703688 conferred higher risk for subarachnoid hemorrhage (SAH), whereas none of the *DIAPH1* SNPs studied showed association with intracerebral hemorrhage (ICH) (Supplementary Table 9).

#### Association analysis of *DIAPH1* variants in the cohort study of hypertension and stroke

The clinic-demographic characteristics of participants in the cohort study of hypertension and stroke are shown in Supplementary Table 3. No significant associations between selected *DIAPH1* gene variants and hypertension were observed (Table 3). Regarding stroke, rs251018 GG genotype carriers showed

significantly higher incidence rate than TT/TG carriers after adjusting for age, gender, TC, TG, HDL-C, LDL-C, smoking, drinking, BMI, T2DM, and hypertension. Increased risk for stroke was also found for rs7703688 genotypes in the additive and recessive models (*P*=0.049 and *P*=0.042, respectively; Table 3).

#### Comparison of *DIAPH1* mRNA expression between IS and controls

Comparative analysis of mRNA expression for the selected SNPs was further conducted in 58 controls and 66 IS cases (43 SAO and 23 LAA). Compared with hypertensive controls, the expression of *DIAPH1* mRNA was significantly downregulated in IS [0.773 (0.575, 1.088) vs 0.933 (0.775, 1.117), *P* = 0.003]. Results are depicted in Figure 1. The expression of *DIAPH1* mRNA among the genotypes of rs3805691, rs251018, rs251019, rs11954998, and rs7703688 did not differ significantly, neither in IS cases nor in controls (Supplementary Figure 2). However, the *DIAPH1* mRNA level in SAO was upregulated with rs251019 genotypes, especially in homozygous CC carriers (mean expression levels in TT, TC, and CC carriers were 0.742, 0.889, and 1.765, respectively, *P*<sub>trend</sub> = 0.048; Supplementary Figure 3).

**Table 2. Association analyses of *DIAPH1* SNPs with stroke sub-types in the case-control study.**

Stroke subtypes	SNP	Group	WT/HT/MT	OR (95% CI) <sup>a</sup>		
				Additive model	Dominant model	Recessive model
IS	rs3805691		CC/CT/TT			
		Case	1429/623/109	0.782(0.700-0.874)	0.712(0.622-0.815)	0.883(0.666-1.171)
		Control	1434/990/166	<i>P</i> =1.300×10 <sup>-5</sup>	<i>P</i> =7.986×10 <sup>-7</sup>	<i>P</i> =0.388
	rs251018		TT/TG/GG			
		Case	1533/619/46	1.041(0.916-1.182)	1.066(0.923-1.232)	0.893(0.579-1.378)
		Control	1857/663/70	<i>P</i> =0.539	<i>P</i> =0.386	<i>P</i> =0.609
	rs251019		CC/CT/TT			
		Case	1322/681/206	0.813(0.734-0.900)	0.685(0.600-0.782)	1.084(0.862-1.362)
		Control	1277/1082/231	<i>P</i> =6.200×10 <sup>-5</sup>	<i>P</i> =1.899×10 <sup>-8</sup>	<i>P</i> =0.491
	rs7703688		TT/TC/CC			
Case		1638/509/61	1.721(1.486-1.993)	1.771(1.504-2.086)	3.076(1.790-5.287)	
	Control	2164/401/25	<i>P</i> =4.139×10 <sup>-12</sup>	<i>P</i> =6.923×10 <sup>-12</sup>	<i>P</i> =4.800×10 <sup>-5</sup>	
rs11954998		TT/TC/CC				
	Case	1336/763/60	1.537(1.356-1.743)	1.626(1.410-1.874)	1.752(1.159-2.650)	
	Control	1893/644/53	<i>P</i> =2.058×10 <sup>-11</sup>	<i>P</i> =2.275×10 <sup>-11</sup>	<i>P</i> =0.008	
HS	rs3805691		CC/CT/TT			
		Case	411/296/41	0.979(0.809-1.185)	1.023(0.808-1.295)	0.771(0.449-1.322)
		Control	1434/990/166	<i>P</i> =0.830	<i>P</i> =0.850	<i>P</i> =0.344
	rs251018		TT/TG/GG			
		Case	548/176/24	0.941(0.745-1.189)	0.945(0.726-1.231)	0.831(0.372-1.855)
		Control	1857/663/70	<i>P</i> =0.978	<i>P</i> =0.677	<i>P</i> =0.652
	rs251019		CC/CT/TT			
		Case	392/284/67	0.972(0.814-1.160)	0.940(0.743-1.188)	1.042(0.691-1.569)
		Control	1277/1082/231	<i>P</i> =0.754	<i>P</i> =0.604	<i>P</i> =0.845
	rs7703688		TT/TC/CC			
Case		610/126/15	1.103(0.832-1.463)	1.078(0.787-1.476)	1.633(0.605-4.411)	
	Control	2164/401/25	<i>P</i> =0.494	<i>P</i> =0.640	<i>P</i> =0.333	
rs11954998		TT/TC/CC				
	Case	547/181/20	1.101(0.870-1.393)	1.107(0.853-1.438)	1.238(0.549-2.791)	
	Control	1893/644/53	<i>P</i> =0.424	<i>P</i> =0.445	<i>P</i> =0.606	

IS: ischemic stroke; HS: hemorrhagic stroke. The allele frequencies of all SNPs in controls were consistent with *HWE*; *HWE P*-values for rs3805691, rs251018, rs251019, rs7703688, and rs11954998 were 0.780, 0.244, 0.933, 0.184, and 0.837 respectively.

a: Adjusted for age, gender, smoking status, drinking status, TC, TG, LDL-C, HDL-C, T2DM, and hypertension.

## DISCUSSION

The current study conducted case-control and cohort studies to investigate the associations of *DIAPH1* polymorphisms with hypertension and stroke. The key findings showed indicated that rs7703688 was significantly associated with risk of stroke, especially with IS. The significant association between rs7703688

and stroke was further validated in the cohort study. Our study also noted, for the first time, that *DIAPH1* mRNA expression is downregulated in IS, implying that *DIAPH1* might affect its pathogenesis.

Previous studies have identified an essential role for *DIAPH1* in actin cytoskeletal remodeling, arterial SMC cell migration, and as a mediator of myocardial

**Table 3. Association analyses of *DIAPH1* SNPs and hypertension and stroke in the cohort study.**

End point	SNP	Genotype	N	Person-years	Incidence density (/10 <sup>4</sup> )	HR (95% CI)		
						Additive model	Dominant model	Recessive model
Hypertension	rs3805691	CC	347	5059.10	685.89	1.019 (0.896-1.166)	1.022 (0.874-1.206)	1.031 (0.734-1.447)
		CT	230	3383.53	682.72	<i>P</i> =0.744 <sup>a</sup>	<i>P</i> =0.748 <sup>a</sup>	<i>P</i> =0.862 <sup>a</sup>
		TT	36	551.32	652.98			
	rs251018	TT	435	6315.13	690.41	0.964 (0.831-1.118)	0.960 (0.806-1.144)	0.937 (0.605-1.453)
		TG	157	2352.28	667.44	<i>P</i> =0.630 <sup>a</sup>	<i>P</i> =0.650 <sup>a</sup>	<i>P</i> =0.772 <sup>a</sup>
		GG	21	326.53	643.13			
	rs251019	CC	306	4311.25	712.09	0.910 (0.808-1.026)	0.872 (0.744-1.022)	0.920 (0.712-1.19)
		CT	241	3724.56	647.06	<i>P</i> =0.123 <sup>a</sup>	<i>P</i> =0.092 <sup>a</sup>	<i>P</i> =0.525 <sup>a</sup>
		TT	66	958.13	688.84			
	rs7703688	TT	503	7373.11	683.57	0.877 (0.728-1.056)	0.902 (0.733-1.111)	0.489 (0.218-1.095)
		TC	104	1470.03	707.47	<i>P</i> =0.166 <sup>a</sup>	<i>P</i> =0.333 <sup>a</sup>	<i>P</i> =0.082 <sup>a</sup>
		CC	6	148.27	404.67			
	rs1195499 8	TT	446	6488.01	688.96	0.877 (0.745-1.032)	0.865 (0.723-1.035)	0.837 (0.46-1.524)
		TC	156	2335.90	667.84	<i>P</i> =0.113 <sup>a</sup>	<i>P</i> =0.113 <sup>a</sup>	<i>P</i> =0.561 <sup>a</sup>
		CC	11	170.04	646.91			
Stroke	rs3805691	CC	104	11943.44	87.07	1.025 (0.796-1.319)	0.887 (0.663-1.186)	1.166 (0.655-2.075)
		CT	64	7919.26	80.82	<i>P</i> =0.851 <sup>b</sup>	<i>P</i> =0.419 <sup>b</sup>	<i>P</i> =0.601 <sup>b</sup>
		TT	15	1281.25	117.07			
	rs251018	TT	133	14859.96	89.50	1.239 (0.943-1.627)	1.178 (0.858-1.615)	2.224 (1.081-4.574)
		TG	44	5689.45	77.34	<i>P</i> =0.124 <sup>b</sup>	<i>P</i> =0.311 <sup>b</sup>	<i>P</i> =0.030 <sup>b</sup>
		GG	6	598.16	100.31			
	rs251019	CC	90	10196.63	88.26	1.111 (0.894-1.381)	1.103 (0.829-1.469)	1.264 (0.791-2.018)
		CT	74	8973.51	82.46	<i>P</i> =0.343 <sup>b</sup>	<i>P</i> =0.501 <sup>b</sup>	<i>P</i> =0.327 <sup>b</sup>
		TT	19	1977.42	96.08			
	rs7703688	TT	149	17468.61	85.29	1.385 (1.001-1.918)	1.345 (0.936-1.935)	2.882 (1.038-8.004)
		TC	31	3451.09	89.83	<i>P</i> =0.049 <sup>b</sup>	<i>P</i> =0.109 <sup>b</sup>	<i>P</i> =0.042 <sup>b</sup>
		CC	3	222.77	134.67			
	rs1195499 8	TT	129	15450.27	83.49	0.880 (0.661-1.171)	1.004 (0.731-1.379)	0.215 (0.03-1.541)
		TC	53	5283.27	100.32	<i>P</i> =0.631 <sup>b</sup>	<i>P</i> =0.982 <sup>b</sup>	<i>P</i> =0.126 <sup>b</sup>
		CC	1	414.02	24.15			

a: Adjusted for age, gender, TC, TG, HDL-C, LDL-C, smoking, drinking, BMI and GLU.

b: Adjusted for age, gender, TC, TG, HDL-C, LDL-C, smoking, drinking, BMI, T2DM and hypertension

ischemia/reperfusion injury and vascular and neuroinflammatory dysfunction [16]. Whether *DIAPH1* polymorphisms affect stroke susceptibility had not been so far determined in GWAS. Rs7703688 was associated with an increased risk of IS, and modestly, but still significantly, it correlated with higher incidence of stroke in the cohort study. This suggests that rs7703688 may constitute a positive locus for stroke diagnosis and treatment. Besides, we also observed that *DIAPH1* rs3805691, rs251019 and rs11954998 were associated with IS and with two IS TOAST subtypes, i.e. SAO and LAA. However, we noticed that these three SNPs in IS cases were deviated from *HWE* ( $P < 0.001$ ), thus, the associations of the later three SNPs with IS were still need further validation.

Bioinformatics analysis for rs7703688 showed that it overlaps with a Hidden Markov Model-predicted enhancer in 15 tissues, including brain, a finding that may help elucidate its involvement in stroke. The position weight matrix (PWM)-scanning process showed that the variation at rs7703688 changes the match to the AP-4 and Spz1 motifs (Supplementary Table 4). Of note, our analysis revealed that rs7703688 is related to 4 eQTLs, reported by a single experiment, for *RELL2*, *ARAP3*, *FCHSD1*, and *PCDHGA6* expression. *ARAP3* encodes a phosphoinositide binding protein containing ARF-GAP and RHO-GAP, which cooperate in cell cytoskeleton remodelling and determining cell shape. Therefore, motifs coupled with eQTL data suggest that functional studies looking at whether AP-4 and Spz1 bind differentially to rs7703688 are warranted. Moreover, the GTEx Portal indicates that the rs7703688 variant is linked to lower *ARAP3*


expression in whole blood. Thus, investigating whether *ARAP3* variation contributes to IS risk is also of great interest.

Accumulation of soluble forms of the receptor for advanced glycation end products (RAGEs, also known as AGER) in serum/plasma has been implicated in multiple physiological and pathological processes, including aging, diabetes, neurodegeneration, ischemia/reperfusion injury, among others [17, 18]. *DIAPH1* is a key intracellular signaling effector of RAGE [19]. Mutation in the cytoplasmic domain of RAGE involving alanine substitution of R5/Q6 residues inhibits physical interaction with *DIAPH1* (FH1 domain) and RAGE ligand-stimulated signal transduction. Our previous study focused on the relationship between *RAGE* genetic variations and hypertension [20]. Positive associations between *RAGE* variations and IS have been observed as well [21].

Our expression analyses of *DIAPH1* mRNA in PBMCs from IS cases and hypertensive controls showed that *DIAPH1* mRNA expression was significantly downregulated in IS. We speculate that *DIAPH1* downregulation would lead to RAGEs accumulation, increasing IS risk. Besides, since *DIAPH1* is also involved in the platelet release process [11], its downregulation might enhance platelet production and promote thrombosis. On the other hand, *DIAPH1* silencing improved intracellular calcium homeostasis in cardiomyocytes following I/R injury [15, 22], which suggests that *DIAPH1* downregulation may be beneficial in ischemic contexts.

Since *DIAPH1* mRNA expression has an increased trend across rs251019 genotypes in SAO, especially in homozygous carriers, which might be considered as a novel eQTL for this IS subtype. Of note, a correlation between rs251019 and both *HDAC3* and *TAF7* expression has been reported [23], while another study showed that the *HDAC3* rs2530223 SNP was associated with CpG site cg24137543, which is close to the transcription start site of *DIAPH1* [24]. Although rs251019 showed a big deviation from *HWE* in our study, the significant result of rs251019 in SAO patients would still inspire us to conduct further function studies to explore its role in stroke.

The distinct advantages of the current study are reflected in the following aspects. First, the positive *DIAPH1* loci associated with stroke could be mutually validated by the case-control and cohort study design. Second, this genetic association study contains a relatively large number of IS and HS cases from south China, further classified by clinical sub-phenotype (SAO and LAA; SAH and ICH). The novel associations



**Figure 1. Comparison of *DIAPH1* mRNA expression between ischemic stroke cases and controls.** The expression of *DIAPH1* mRNA ( $2^{-\Delta\Delta CT}$ ) in PBMCs was significantly downregulated in IS compared with controls [0.773 (0.575, 1.088) vs 0.933 (0.775, 1.117);  $P = 0.003$ ]. IS, ischemic stroke.

detected between *DIAPH1* rs7703688 and stroke may provide further insight about molecular differences between etiological stroke subtypes, especially in the Asian population.

Several limitations are also apparent in our study. First, by selecting candidate SNPs with the criterion  $MAF \geq 0.05$  we may have missed the chance of evaluating rare variants in *DIAPH1* also associated to stroke or hypertension. Second, all participants were from the south China Han population, so the present findings might not be representative of other demographic groups. Third, rs7703688 was not in *HWE* neither in controls within the case-control study of hypertension. Although the association of rs7703688 with stroke was further validated in the cohort study, the *P* values were not significant after multiple testing correction. Indeed, we should be cautious about the association of rs7703688 with stroke, until larger scale population studies validate these findings.

In conclusion, the current study reports original evidence for the association of genetic variation in the *DIAPH1* gene with stroke risk, especially the SAO subtype of IS. In parallel, down regulation of *DIAPH1* expression was observed in IS, suggesting that *DIAPH1* mRNA level might be a potential biomarker for IS diagnosis. Further work to elucidate the specific influence of *DIAPH1* gene variation on cerebrovascular conditions may help discover new pharmacological targets and design better therapies against stroke.

## MATERIALS AND METHODS

### Study population

Case-control and cohort studies were conducted to investigate the association of polymorphisms in the *DIAPH1* gene with hypertension and stroke. A total of 4,128 participants from the community hypertension survey were recruited between 2009 and 2010 from Guanlin and Xushe towns in Yixing city (Jiangsu, China). In the case-control study of hypertension, 2,012 patients with hypertension and 2,116 controls were recruited. Hypertension was determined as systolic blood pressure (SBP)  $\geq 140$  mmHg and/or diastolic blood pressure (DBP)  $\geq 90$  mmHg, or currently receiving anti-hypertensive medication. Subjects who had a clinical history of secondary hypertension were excluded. As the average age was higher in hypertension cases than in controls, 94 elder controls were selected from local communities for age-matching with hypertension cases. The demographic characteristics of the sample population are listed in Supplementary Table 1, and have been previously reported [25].

In the case-control study of stroke, 2,212 IS and 754 HS cases were recruited between 2013 and 2017 in the People's Hospital of Yixing City. All stroke cases were admitted with first-time acute stroke within 72 hours. Individuals older than 85 years were excluded from the study. 2,590 age ( $\pm 5$  years)- and gender-matched controls were selected from community members. The demographic and clinical characteristics of the studied population are summarized in Supplementary Table 2.

IS and HS sub-types were confirmed by a neurologist according to medical records of computed tomography (CT) and/or magnetic resonance imaging (MRI). As per TOAST criteria [26], 2,212 IS cases were classified into 1,199 SAO, 882 LAA, 108 cardiogenic cerebral embolisms (CE), 12 strokes of undetermined etiology (SUE), and 11 strokes of other determined etiology (SOE). In turn, 754 HS cases were classified into 103 SAH and 651 intracerebral hemorrhages (ICH).

For cohort studies, 2,116 participants with normal blood pressure were enrolled for the hypertension study, while 4,098 subjects were enrolled for the study assessing stroke. The clinic-demographic characteristics of these populations are listed in Supplementary Table 3. During a median follow-up time of 5.01 years, 613 cases of hypertension and 183 strokes (171 IS and 12 HS) were recorded. The flow chart of the study design is outlined in Supplementary Figure 1.

Interviews, physical examinations, and laboratory tests were conducted for all participants. Demographic characteristics including age, gender, smoking status and drinking status were obtained by trained research staff through a standard questionnaire. Weight, height, and blood pressure measurements were obtained by trained assistants according to standard protocols.

Drinking habit was defined as self-reported drinking frequency (current or past consumption of an alcoholic beverage at least 2 times per week for at least 6 months per year). Smoking habit was defined as current or past consumption of at least 20 cigarettes per week for at least 3 months per year.

The research protocol was approved by the ethics committee of Nanjing Medical University. All participants were informed in detail about the investigation and voluntarily signed the informed consent form.

### SNP selection

We selected SNPs covering the *DIAPH1* gene within 5 kb upstream and 2 kb downstream of the 5' and 3' ends of the transcript, respectively, according to the International Hap Map Project database (HapMap Data

Rel 24/phase II Nov08, on NCBI B36 assembly, dbSNPb126). All SNPs were selected with the criteria of minor allele frequency (MAF)  $\geq 0.05$  and linkage disequilibrium (LD)  $r^2 \geq 0.8$ . SNPs with predictive biological effects and functions were obtained from HaploReg v4.1 [27] and rerun as tagSNPs. Finally, five tagSNPs, rs3805691, rs251018, rs251019, rs7703688, and rs11954998 were selected. Corresponding biological information, primers, and probes are summarized in Supplementary Tables 4, 5.

### Blood sampling and SNP genotyping

Blood samples were collected in EDTA-containing receptacles after overnight fasting (>10 h), and TC, TG, HDL-C, LDL-C, and GLU were measured. Stroke cases consented to donate 5 ml venous blood to the Department of Neurology after admission. Anticoagulated samples were stored at  $-20^{\circ}\text{C}$  within 24 h after separating serum and plasma.

Genomic DNA was isolated applying a standard phenol-chloroform method. Genotyping was performed using the TaqMan allelic discrimination assay on a 7900HT Real-time PCR System (Applied Biosystems, Foster City, CA). Each plate included blank samples as negative controls to verify genotyping quality. Call rates for each SNP were  $> 99.9\%$ .

### DIAPH1 mRNA measurement

To explore whether *DIAPH1* was differentially expressed between IS cases and controls, 66 inpatients with newly diagnosed IS were recruited from Yixing People's Hospital (from Jan to Nov. 2017). Considering that hypertension is a dominant characteristic of IS, we selected 58 age- and gender- matched hypertensive controls to compare the expression of *DIAPH1* at the mRNA level. To this end, PBMCs were isolated within 4 h after blood extraction and *DIAPH1* mRNA was isolated and quantified using a standard protocol (Supplementary Methods). Primer sequences for *DIAPH1* and control GAPDH mRNAs are listed in Supplementary Table 6. In addition, DNA genotyping was conducted in both groups to investigate potential association of *DIAPH1* polymorphisms with mRNA level variation. Clinic-demographic characteristics of IS cases and hypertensive controls are summarized in Supplementary Table 7.

### Statistical analysis

Unpaired Student's t-tests were used to assess intergroup differences for quantitative variables, presented as means  $\pm$  SD. HWE for genotype frequencies was estimated with a Fisher's exact test in controls. For

comparisons between not normally distributed independent samples, the Mann–Whitney U test was applied. Unconditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) as well as to adjust for covariates. Cox regression was applied to estimate hazard ratios (HRs) and 95% CIs in the cohort study. A two-tailed *P* value of 0.05 was defined as the cutoff for statistical significance. All statistical analyses were performed with SPSS version 18.0 (SPSS, Inc., Chicago, IL).

### AUTHOR CONTRIBUTIONS

Chong Shen designed the research. Zhuanyun Ren, Xiaotian Chen, and Chunlan Liu performed the majority of the experiments. Yanchun Chen, Xianghai Zhao, Huihua Zong, Wuzhuang Tang, and Song Yang provided clinical specimens and performed clinical observations. Xiaotian Chen and Chunlan Liu and analyzed data. Zhanyun Ren, Xiaotian Chen, and Jie Li wrote and Chong Shen revised the manuscript.

### CONFLICTS OF INTEREST

We declare that the authors do not have financial disclosures and conflicts of interest.

### FUNDING

This work was supported by the National Natural Science Foundation of China (Grant No. 81573232, No. 81673266, No. 81390543, No. 91439202, and No. 81773537), Jiangsu Provincial Fourth “333 Project”, the Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine) and the Flagship Major Development of Jiangsu Higher Education Institutions. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### REFERENCES

1. Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, Wang L, Jiang Y, Li Y, Wang Y, Chen Z, Wu S, Zhang Y, et al, and NESS-China Investigators. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults. *Circulation*. 2017; 135:759–71. <https://doi.org/10.1161/CIRCULATIONAHA.116.025250> PMID:28052979
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, Study HO, and Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J*



- Med. 2000; 342:145–53.  
<https://doi.org/10.1056/NEJM200001203420301>  
PMID:10639539
3. Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. *Trends Pharmacol Sci.* 2011; 32:167–73.  
<https://doi.org/10.1016/j.tips.2010.12.006>  
PMID:21242007
  4. Gien J, Tseng N, Seedorf G, Roe G, Abman SH. Peroxisome proliferator activated receptor- $\gamma$ -Rho-kinase interactions contribute to vascular remodeling after chronic intrauterine pulmonary hypertension. *Am J Physiol Lung Cell Mol Physiol.* 2014; 306:L299–308.  
<https://doi.org/10.1152/ajplung.00271.2013>  
PMID:24375792
  5. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. *Hypertension.* 2001; 38:1307–10.  
<https://doi.org/10.1161/hy1201.096541>  
PMID:11751708
  6. Yang S, Zhao Y, Tian Y, Chen Y, Zhao X, Li Y, Zhao H, Chen X, Zhu L, Fang Z, Yao Y, Hu Z, Shen C. Common variants of ROCKs and the risk of hypertension, and stroke: two case-control studies and a follow-up study in Chinese Han population. *Biochim Biophys Acta Mol Basis Dis.* 2018; 1864:778–83.  
<https://doi.org/10.1016/j.bbadis.2017.12.007>  
PMID:29246448
  7. Young KG, Copeland JW. Formins in cell signaling. *Biochim Biophys Acta.* 2010; 1803:183–90.  
<https://doi.org/10.1016/j.bbamcr.2008.09.017>  
PMID:18977250
  8. Shinohara R, Thumkeo D, Kamijo H, Kaneko N, Sawamoto K, Watanabe K, Takebayashi H, Kiyonari H, Ishizaki T, Furuyashiki T, Narumiya S. A role for mDia, a Rho-regulated actin nucleator, in tangential migration of interneuron precursors. *Nat Neurosci.* 2012; 15:373–80, S1–2.  
<https://doi.org/10.1038/nn.3020>  
PMID:22246438
  9. Goode BL, Eck MJ. Mechanism and function of formins in the control of actin assembly. *Annu Rev Biochem.* 2007; 76:593–627.  
<https://doi.org/10.1146/annurev.biochem.75.103004.142647> PMID:17373907
  10. Touré F, Fritz G, Li Q, Rai V, Daffu G, Zou YS, Rosario R, Ramasamy R, Alberts AS, Yan SF, Schmidt AM. Formin mDia1 mediates vascular remodeling via integration of oxidative and signal transduction pathways. *Circ Res.* 2012; 110:1279–93.  
<https://doi.org/10.1161/CIRCRESAHA.111.262519>  
PMID:22511750
  11. Pan J, Lordier L, Meyran D, Rameau P, Lecluse Y, Kitchen-Goosen S, Badirou I, Mokrani H, Narumiya S, Alberts AS, Vainchenker W, Chang Y. The formin DIAPH1 (mDia1) regulates megakaryocyte proplatelet formation by remodeling the actin and microtubule cytoskeletons. *Blood.* 2014; 124:3967–77.  
<https://doi.org/10.1182/blood-2013-12-544924>  
PMID:25298036
  12. Stritt S, Nurden P, Turro E, Greene D, Jansen SB, Westbury SK, Petersen R, Astle WJ, Marlin S, Bariana TK, Kostadima M, Lentaigne C, Maiwald S, et al, and BRIDGE-BPD Consortium. A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss. *Blood.* 2016; 127:2903–14.  
<https://doi.org/10.1182/blood-2015-10-675629>  
PMID:26912466
  13. Al-Maawali A, Barry BJ, Rajab A, El-Quessny M, Seman A, Coury SN, Barkovich AJ, Yang E, Walsh CA, Mochida GH, Stoler JM. Novel loss-of-function variants in DIAPH1 associated with syndromic microcephaly, blindness, and early onset seizures. *Am J Med Genet A.* 2016; 170A:435–40.  
<https://doi.org/10.1002/ajmg.a.37422> PMID:26463574
  14. Lin YN, Izbicki JR, König A, Habermann JK, Blechner C, Lange T, Schumacher U, Windhorst S. Expression of DIAPH1 is up-regulated in colorectal cancer and its down-regulation strongly reduces the metastatic capacity of colon carcinoma cells. *Int J Cancer.* 2014; 134:1571–82.  
<https://doi.org/10.1002/ijc.28486>  
PMID:24105619
  15. O'Shea KM, Ananthkrishnan R, Li Q, Quadri N, Thiagarajan D, Sreejit G, Wang L, Zirpoli H, Aranda JF, Alberts AS, Schmidt AM, Ramasamy R. The Formin, DIAPH1, is a Key Modulator of Myocardial Ischemia/Reperfusion Injury. *EBioMedicine.* 2017; 26:165–74.  
<https://doi.org/10.1016/j.ebiom.2017.11.012>  
PMID:29239839
  16. MacLean M, Derk J, Ruiz HH, Juraneck JK, Ramasamy R, Schmidt AM. The Receptor for Advanced Glycation End Products (RAGE) and DIAPH1: implications for vascular and neuroinflammatory dysfunction in disorders of the central nervous system. *Neurochem Int.* 2019; 126:154–64.  
<https://doi.org/10.1016/j.neuint.2019.03.012>  
PMID:30902646
  17. Reichert S, Triebert U, Santos AN, Hofmann B, Schaller HG, Schlitt A, Schulz S. Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients

- with cardiovascular disease. *Atherosclerosis*. 2017; 266:234–39.  
<https://doi.org/10.1016/j.atherosclerosis.2017.08.015>  
PMID:28864204
18. Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK, Hwang YC, Lerner S, Bakr S, Li Q, Lu Y, Song F, Qu W, Gomez T, et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. *Circulation*. 2006; 113:1226–34.  
<https://doi.org/10.1161/CIRCULATIONAHA.105.575993>  
PMID:16505177
19. Ramasamy R, Shekhtman A, Schmidt AM. The multiple faces of RAGE—opportunities for therapeutic intervention in aging and chronic disease. *Expert Opin Ther Targets*. 2016; 20:431–46.  
<https://doi.org/10.1517/14728222.2016.1111873>  
PMID:26558318
20. Yang S, Wang H, Yang Y, Wang W, Jiang J, Zhao X, Du Q, Wang X, Yao Y, Shen H, Shen C, Zhao Y. Association study of AGER gene polymorphism and hypertension in Han Chinese population. *Gene*. 2012; 498:311–16.  
<https://doi.org/10.1016/j.gene.2012.01.080>  
PMID:22353366
21. Li Y, Zhu J, Chen L, Hu W, Wang M, Li S, Gu X, Tao H, Zhao B, Ma G, Li K. Genetic predisposition to ischaemic stroke by RAGE and HMGB1 gene variants in Chinese Han population. *Oncotarget*. 2017; 8:100150–64.  
<https://doi.org/10.18632/oncotarget.22112>  
PMID:29245967
22. Blaustein MP, Lederer WJ. Sodium/calcium exchange: its physiological implications. *Physiol Rev*. 1999; 79:763–854.  
<https://doi.org/10.1152/physrev.1999.79.3.763>  
PMID:10390518
23. Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, Christiansen MW, Fairfax BP, Schramm K, Powell JE, Zernakova A, Zernakova DV, Veldink JH, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nat Genet*. 2013; 45:1238–43.  
<https://doi.org/10.1038/ng.2756> PMID:24013639
24. Ciuculete DM, Boström AE, Voisin S, Philipps H, Titova OE, Bandstein M, Nikontovic L, Williams MJ, Mwinyi J, Schiöth HB. A methylome-wide mQTL analysis reveals associations of methylation sites with GAD1 and HDAC3 SNPs and a general psychiatric risk score. *Transl Psychiatry*. 2017; 7:e1002.  
<https://doi.org/10.1038/tp.2016.275> PMID:28094813
25. Chen J, Zhao X, Wang H, Chen Y, Wang W, Zhou W, Wang X, Tang J, Zhao Y, Lu X, Chen S, Wang L, Shen C, Yang S. Common variants in TGFBR2 and miR-518 genes are associated with hypertension in the Chinese population. *Am J Hypertens*. 2014; 27:1268–76.  
<https://doi.org/10.1093/ajh/hpu047>  
PMID:24687999
26. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke*. 1993; 24:35–41.  
<https://doi.org/10.1161/01.STR.24.1.35>  
PMID:7678184
27. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res*. 2012; 40:D930–34.  
<https://doi.org/10.1093/nar/gkr917>  
PMID:22064851

## SUPPLEMENTARY MATERIALS


### METHODS

#### Determination of *DIAPH1* mRNA expression in peripheral blood mononuclear cells


Total RNA was isolated from peripheral mononuclear cells (100µl) using the RNA Blood Kit (Cat#Yu-B02-1, Yuan Corp., Wuxi, China) according to the manual's instructions. A total of 0.3 µg total RNA was used for cDNA synthesis using TAKARA reverse transcription kits (RR047A Takara PrimeScript™ RT reagent Kit with gDNA Eraser, Japan). Primers were designed on Primer Premier 5.0 software and are shown in Supplementary Table 2. The qPCR reactions were

performed in a 10 µl reaction mixture of 2 µl cDNA, 5 µl Hieff™ qPCR SYBR® GEEN Master Mix, 2.6 µl nuclease-free water, 0.2 µl upstream primer, and 0.2 µl downstream primer. The qPCR conditions were 95°C for 5 min, 95°C for 10 s, 60°C for 20 s and 72°C for 20 s (40 cycles). A melting curve cycle at 95°C for 15 s, 60°C for 1 min, and 95°C for 15 s was generated post-amplification. Three parallel samples were set up with a standard deviation <0.5, and the average value was calculated. The expression of *DIAPH1* mRNA was calculated with the  $2^{-\Delta\Delta CT}$  method ( $\Delta CT = CT_{\text{target gene}} - CT_{\text{house keeper gene}}$ ,  $\Delta\Delta CT = \Delta CT - \Delta CT_{\text{control average value}}$ ).


## SUPPLEMENTARY FIGURES



**Supplementary Figure 1. Flow chart for participant selection in case-control and cohort studies evaluating associations between *DIAPH1* SNPs and hypertension and stroke.** Age-matched elderly controls (n = 94) included in the hypertension case-control study, as well as hypertension cases with history of stroke (n = 30), were excluded in the cohort study of stroke.



Supplementary Figure 2. Comparison of relative *DIAPH1* mRNA relative expression amongst rs3805691, rs251018, rs251019, rs11954998 and rs7703688 genotypes in IS cases and controls.



**Supplementary Figure 3. Comparison of relative *DIAPH1* mRNA expression amongst rs3805691, rs251018, rs251019, rs11954998 and rs7703688 genotypes in IS subtypes and controls.** *DIAPH1* mRNA level in SAO has an increased trend among rs251019 genotypes; mean expression levels for TT, TC, and CC carriers were 0.742, 0.889, and 1.765, respectively ( $P_{trend} = 0.048$ ).

## SUPPLEMENTARY TABLES

**Supplementary Table 1. Demographic and clinical characteristics of the case-control study of hypertension.**

Characteristics	Group	Hypertension	Normotension	<i>t</i> / $\chi^2$	<i>P</i>
		n = 2,012	n=2,210		
Age (year)		62.35±10.73	58.93±10.45	10.484	<0.001
Gender (%)	Male	829(41.20%)	884(40.00%)	0.632	0.427
	Female	1,183(58.80%)	1,326(60.00%)		
SBP (mm Hg)		142.86±14.30	124.24±11.36	47.018	<0.001
DBP (mm Hg)		87.53±8.54	79.08±6.51	36.369	<0.001
BMI (kg/m <sup>2</sup> )		24.76±3.51	23.64±3.20	10.844	<0.001
TC (mmol/L)		4.94±1.05	4.78±1.01	4.574	<0.001
TG (mmol/L)		1.86±1.58	1.53±1.21	7.618	<0.001
HDL-C (mmol/L)		1.36±0.33	1.36±0.33	0.175	0.751
LDL-C (mmol/L)		2.80±0.89	2.64±0.73	6.227	<0.001
GLU (mmol/L)		5.83±2.05	5.46±1.61	6.684	<0.001
Smokers (%)	Yes	480(23.86%)	533(24.12%)	0.039	0.843
	No	1,532(76.14%)	1,677(75.88%)		
Drinkers (%)	Yes	424(21.07%)	477(21.58%)	0.163	0.686
	No	1,588(78.93%)	1,733(78.42%)		
T2DM	Yes	272 (13.52%)	196 (8.86%)	23.106	<0.001
	No	1740 (86.48%)	2014 (91.14%)		
Antihypertension medications	Compound reserpine	307 (15.26%)	-	-	-
	Zhen Ju Jiang Ya tablets	112 (5.57%)	-	-	-
	Jiang Ya tablets	221 (10.98%)	-	-	-
	Other medications	398 (19.78%)	-	-	-
	Untreated	974 (48.41%)	-	-	-

BMI, body mass index; DBP, diastolic blood pressure; GLU, glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; T2DM, type 2 diabetes mellitus. Zhen Ju Jiang Ya tablets and Jiang Ya tablets natural herbal supplements used in traditional Chinese medicine.

**Supplementary Table 2. Demographic and clinical characteristics of the case-control study of stroke.**

Characteristics	Group	Controls	IS	HS	F/ $\chi^2$	P
		n=2,590	n=2,212	n=754		
Age (year)		66.08±10.30	66.53±10.30	63.00±13.77**	30.931	<0.001
Gender (%)	Male	965(37.26%)	1327(59.99%)	453(60.08%)	286.404	<0.001
	Female	1,625(62.74%)	885(40.01%)	301(39.92%)		
TC (mmol/L)		0.95±0.02	1.91±0.04*	1.07±0.06*	7.287	0.001
TG (mmol/L)		1.33±0.03	1.66±0.04	1.23±0.05**	8.170	<0.001
HDL-C(mmol/L)		0.34±0.01	0.35±0.01**	0.44±0.02*	91.513	<0.001
LDL-C (mmol/L)		0.77±0.01	2.00±0.05*	0.82±0.04	5.004	0.007
Smokers (%)	Yes	573(22.12%)	531(24.00%)	124(16.44%)	17.82	<0.001
	No	2,017(77.88%)	1,681(76.00%)	630(83.56%)		
Drinkers (%)	Yes	526(20.31%)	342(15.46%)	96(12.73%)	31.776	<0.001
	No	2,064(79.69%)	1,870(85.54%)	658(87.27%)		
Hypertension (%)	Yes	1,218(47.03%)	1,536(69.44%)	486(64.46%)	263.074	<0.001
	No	1,372(52.97%)	676(30.56%)	268(35.54%)		
T2DM (%)	Yes	299(11.54%)	586(26.49%)	93(12.33%)	199.766	<0.001
	No	2,291(88.46%)	1,626(73.51%)	661(87.67%)		

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride; T2DM, type 2 diabetes mellitus; IS: ischemic stroke; HS: hemorrhagic stroke.

\* and \*\* indicates that statistical differences when compared to controls.

**Supplementary Table 3. Clinical and demographic characteristics of the cohort study of hypertension and stroke.**

Characteristics	Group	Hypertension	Stroke
		n=2,116	n=4,098
Age (year)		58.41±10.28	60.27±10.67
Gender (%)	Male	853(40.31%)	1660(40.51%)
	Female	1,263(59.69%)	2,438(59.49%)
BMI (kg/m <sup>2</sup> )		23.70±3.21	22.21±3.38
TC (mmol/L)		4.78±1.01	4.85±1.03
TG (mmol/L)		1.54±1.21	1.69±1.41
HDL-C (mmol/L)		1.37±0.33	1.37±0.33
LDL-C (mmol/L)		2.65±0.72	2.72±0.81
GLU (mmol/L)		5.47±1.62	5.65±1.86
Smokers (%)	Yes	525(24.81%)	995(24.28%)
	No	1,591(75.19%)	3103(75.72%)
Drinkers (%)	Yes	468(22.12%)	883(21.55%)
	No	1,648(77.88%)	3,215(78.45%)
Hypertension (%)	Yes	-	1,985(48.43%)
	No	2,166(100%)	2,113(51.56%)
T2DM (%)	Yes	193(9.12%)	461(11.98%)
	No	1,923(90.88%)	3,637(88.02%)

BMI, body mass index; DBP, diastolic blood pressure; GLU, glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride, T2DM, type 2 diabetes mellitus.



**Supplementary Table 4. Biological information and function prediction for selected tagSNPs.**

SNP	Chr	dbSNP function	Allele	eQTL hits	Motifs changed	Promoter histone marks	Enhancer histone marks
rs3805691	5	intronic	C/T	--	Cart1, Hltf, Irf, STAT	7 tissues	14 tissues
rs251018	5	intronic	T/G	4 hits	Foxp3, Nanog, Pou5f1	STRM	16 tissues
rs251019	5	intronic	C/T	2 hits	13 altered motifs	BLD	13 tissues
rs7703688	5	intronic	T/C	4 hits	AP-4, Spz1	--	15 tissues
rs11954998	5	intronic	T/C	--	--	--	FAT

SNP, single nucleotide polymorphism; eQTL, expression quantitative trait locus; 1000G Phase 1 population for LD calculation was set as ASN.

**Supplementary Table 5. Primers and probes of selected tagSNPs in DIAPH1.**

SNP		Sequence(5'-3')	
rs3805691	probe	CCAGTAATTGAAATCATATG	CCAGTAATTGAAACCATAT
	primer	GGTAGGGAATCTGCAGCAAGAA	TTTCACTACCAGAAGCATGTCTTTG
rs251018	probe	CTGCATCAGACTTT	CCTGCATCAGAATT
	primer	TTGACCCCGTCGGCTAAGT	ATAGTTCCACAGGAAGAGGCTTAAAAG
rs251019	probe	ACAAGAAACATAATTAGGAGAGT	ACAAGAAACATAATTAGCAGAG
	primer	GCTTATTCTCCCCCTACTTTTGTA	AGGGAAGAGGAACTAGGACAGATG
rs7703688	probe	TGAGGGTAACATAGCTA	TGAGGGTAACACAGCTA
	primer	CAGAACACTTAATAATCTCTCCAGGAAT	GGCTTATTGTATGCTAGGTGAACTTG
rs11954998	probe	TGCAAATATGGCCCTATGT	TGCAAATATGGCCCATG
	primer	TTGTGATCCGCCACCTT	GCTTATTCTCCCCCTACTTTTCGTA

**Supplementary Table 6. Primer sequences for mRNA quantification.**

Gene	Primer sequences (5'-3')	Amplification products	T <sub>m</sub>
<i>DIAPH1</i>	F: GGAGTTACGATAGCCGGAACA	96bp	60°C
	R: CTTCTGTCTCCAACATGGTCTTG		
<i>GAPDH</i>	F: ACACACTCAGTGAACA	76bp	60°C
	R: ATGGACTCATCTTTGCCTATTGC		

**Supplementary Table 7. Sample characteristics of the *DIAPH1* mRNA analysis**

Characteristics	Group	IS	Controls	<i>t/χ</i> <sup>2</sup>	<i>P</i>
		n=66	n=58		
Age (year)		65.31±6.83	64.65±7.41	0.516	0.607
Gender (%)	Male	37(56.06%)	27(46.55%)	1.118	0.290
	Female	29(43.94%)	31(53.45%)		
Smokers (%)	Yes	13(19.69%)	11(18.96%)	0.011	0.918
	No	53(80.31%)	47(81.04%)		
Drinkers (%)	Yes	21(31.82%)	18(31.03%)	5.552	0.018
	No	45(68.18%)	40(68.97%)		
Diabetes (%)	Yes	12(18.18%)	6(10.34%)	1.528	0.216
	No	54(81.82%)	52(89.66%)		
IS subtype	SAO	43(65.15%)	-	-	-
	LAA	23(34.85%)	-	-	-

IS, ischemic stroke; LAA, large-artery atherosclerosis; SAO, small artery occlusion.

**Supplementary Table 8. Association analysis of *DIAPH1* SNPs and IS subtypes in the case-control study.**

TOAST subtypes	SNP	Group	WT/HT/MT	OR (95% CI) <sup>a</sup>		
				Additive model	Dominant model	Recessive model
SAO	rs3805691		CC/CT/TT			
		Case	794/326/56	0.758(0.663-0.866)	0.686(0.583-0.806)	0.844(0.599-1.190)
		Control	1434/990/166	$P=4.400\times 10^{-5}$	$P=5.000\times 10^{-6}$	$P=0.333$
	rs251018		TT/TG/GG			
		Case	821/663/22	1.070(0.920-1.243)	1.109(0.936-1.314)	0.844(0.494-1.442)
		Control	1857/663/70	$P=0.380$	$P=0.233$	$P=0.534$
	rs251019		CC/CT/TT			
		Case	714/374/110	0.817(0.724-0.922)	0.690(0.590-0.806)	1.096(0.837-1.436)
		Control	1277/1082/231	$P=0.001$	$P=3.000\times 10^{-6}$	$P=0.505$
	rs7703688		TT/TC/CC			
		Case	869/296/32	1.777(1.502-2.103)	1.865(1.545-2.252)	2.810(1.534-5.149)
		Control	2164/401/25	$P=2.001\times 10^{-11}$	$P=8.974\times 10^{-11}$	$P=0.001$
rs11954998		TT/TC/CC				
	Case	705/433/31	1.571(1.356-1.815)	1.675(1.421-1.984)	1.675(1.029-2.728)	
	Control	1893/644/53	$P=1.760\times 10^{-9}$	$P=1.139\times 10^{-9}$	$P=0.038$	
LAA	rs3805691		TT/TC/CC			
		Case	558/259/46	0.847(0.731-0.981)	0.774(0.646-0.927)	1.015(0.702-1.468)
		Control	1434/990/166	$P=2.700\times 10^{-4}$	$P=0.005$	$P=0.935$
	rs251018		TT/TC/CC			
		Case	613/245/20	1.006(0.847-1.194)	1.015(0.836-1.231)	0.953(0.535-1.697)
		Control	1857/663/70	$P=0.945$	$P=0.883$	$P=0.870$
	rs251019		TT/TC/CC			
		Case	521/278/81	0.794(0.693-0.911)	0.673(0.564-0.803)	1.018(0.749-1.385)
		Control	1277/1082/231	$P=0.001$	$P=1.100\times 10^{-5}$	$P=0.908$
	rs7703688		TT/TC/CC			
		Case	659/194/27	1.805(1.498-2.175)	1.831(1.483-2.262)	3.715(1.984-6.956)
		Control	2164/401/25	$P=5.710\times 10^{-10}$	$P=1.955\times 10^{-8}$	$P=4.100\times 10^{-5}$
rs11954998		TT/TC/CC				
	Case	562/280/24	1.446(1.225-1.708)	1.500(1.242-1.812)	1.751(1.027-3.988)	
	Control	1893/644/53	$P=1.400\times 10^{-6}$	$P=2.600\times 10^{-5}$	$P=0.040$	

SAO, small artery occlusion; LAA, large-artery atherosclerosis.

a, adjusted for age, gender, TC, TG, HDL-C, LDL-C, smoking status, drinking status, T2DM and hypertension.

**Supplementary Table 9. Association analysis of *DIAPH1* SNPs and HS subtypes in the case-control study.**

HS subtypes	SNP	Group	WT/HT/MT	OR (95% CI) <sup>a</sup>		
				Additive model	Dominant model	Recessive model
SAH	rs3805691		CC/CT/TT			
		Case	64/32/6	0.555(0.289-1.065)	0.590(0.287-1.210)	0.963(0.412-2.252)
		Control	1434/990/166	<i>P</i> =0.077	<i>P</i> =0.150	<i>P</i> =0.931
	rs251018		TT/TG/GG			
		Case	78/16/7	0.908(0.454-1.813)	0.858(0.392-1.878)	1.254(0.164-9.572)
		Control	1857/663/70	<i>P</i> =0.784	<i>P</i> =0.702	<i>P</i> =0.827
	rs251019		CC/CT/TT			
		Case	56/30/15	0.953(0.566-1.604)	0.772(0.390-1.528)	1.558(0.567-4.285)
		Control	1277/1082/231	<i>P</i> =0.855	<i>P</i> =0.457	<i>P</i> =0.390
	rs7703688		TT/TC/CC			
		Case	79/17/6	1.602(1.801-3.205)	1.362(0.592-3.134)	6.487(1.371-30.706)
		Control	2164/401/25	<i>P</i> =0.184	<i>P</i> =0.467	<i>P</i> =0.018
rs11954998		TT/TC/CC				
	Case	71/26/6	1.066(0.550-2.069)	0.902(0.420-1.940)	3.150(0.676-14.679)	
	Control	1893/644/53	<i>P</i> =0.849	<i>P</i> =0.792	<i>P</i> =0.144	
ICH	rs3805691		CC/CT/TT			
		Case	347/264/35	1.019(0.826-1.258)	1.077(0.834-1.392)	0.807(0.454-1.432)
		Control	1434/990/166	<i>P</i> =0.858	<i>P</i> =0.569	<i>P</i> =0.463
	rs251018		TT/TG/GG			
		Case	470/160/17	0.982(0.763-1.264)	1.001(0.752-1.332)	0.806(0.331-1.963)
		Control	1857/663/70	<i>P</i> =0.890	<i>P</i> =0.996	<i>P</i> =0.635
	rs251019		CC/CT/TT			
		Case	336/254/52	0.926(0.800-1.070)	1.002(0.776-1.295)	1.075(0.680-1.698)
		Control	1277/1082/231	<i>P</i> =0.296	<i>P</i> =0.986	<i>P</i> =0.757
	rs7703688		TT/TC/CC			
		Case	531/109/9	0.958(0.695-1.319)	0.952(0.672-1.350)	0.962(0.255-3.626)
		Control	2164/401/25	<i>P</i> =0.792	<i>P</i> =0.783	<i>P</i> =0.954
rs11954998		TT/TC/CC				
	Case	476/155/14	1.109(0.859-1.433)	1.140(0.857-1.516)	0.940(0.349-2.532)	
	Control	1893/644/53	<i>P</i> =0.429	<i>P</i> =0.365	<i>P</i> =0.902	

SAH, subarachnoid hemorrhage; ICH, intracerebral hemorrhage.

a: adjusted for age, gender, TC, TG, HDL-C, LDL-C, smoking status, drinking status, T2DM and hypertension.